Cargando…

Migrating to Long-Read Sequencing for Clinical Routine BCR-ABL1 TKI Resistance Mutation Screening

OBJECTIVE: The aim of this project was to implement long-read sequencing for BCR-ABL1 TKI resistance mutation screening in a clinical setting for patients undergoing treatment for chronic myeloid leukemia. MATERIALS AND METHODS: Processes were established for registering and transferring samples fro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schaal, Wesley, Ameur, Adam, Olsson-Strömberg, Ulla, Hermanson, Monica, Cavelier, Lucia, Spjuth, Ola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290162/ https://www.ncbi.nlm.nih.gov/pubmed/35860345 http://dx.doi.org/10.1177/11769351221110872

Ejemplares similares

Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing
por: Cavelier, Lucia, et al.
Publicado: (2015)

BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon
por: Stanchina, Michele, et al.
Publicado: (2020)

Flow Cytometric Measurement of Blood Cells with BCR-ABL1 Fusion Protein in Chronic Myeloid Leukemia
por: Löf, Liza, et al.
Publicado: (2017)

Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts
por: Massimino, Michele, et al.
Publicado: (2021)

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition
por: Mitchell, Rebecca, et al.
Publicado: (2017)

Susceptibility Of Ph-Positive All To Tki Therapy Associated With Bcr-Abl Rearrangement Patterns: A Retrospective Analysis
por: Jing, Yu, et al.
Publicado: (2014)

BCR‐ABL exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia and TKI resistance
por: Mikhailov, Ilya
Publicado: (2018)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Droplet Digital PCR for BCR–ABL1 Monitoring in Diagnostic Routine: Ready to Start?
por: Bochicchio, Maria Teresa, et al.
Publicado: (2021)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance
por: Parker, W T, et al.
Publicado: (2013)

Large-scale virtual screening on public cloud resources with Apache Spark
por: Capuccini, Marco, et al.
Publicado: (2017)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

Atypical chronic myeloid leukemia BCR-ABL 1 negative: A case report and literature review
por: Belkhair, Jihane, et al.
Publicado: (2019)

P685: LATE PHASE BCR-ABL DECLINE PREDICTS THE DURATION OF TKI (IMATINIB) FOR SUCCESSFUL TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA.
por: R, Chethan, et al.
Publicado: (2023)

MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia
por: Mazzera, Laura, et al.
Publicado: (2023)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
por: Deng, Xianming, et al.
Publicado: (2010)

An In-House Method for Molecular Monitoring of BCR-ABL
por: Sercan, Hakkı Ogün, et al.
Publicado: (2012)

Depression of oncogenecity by dephosphorylating and degrading BCR-ABL
por: Gao, Miao, et al.
Publicado: (2016)

Automated QuantMap for rapid quantitative molecular network topology analysis
por: Schaal, Wesley, et al.
Publicado: (2013)

Tracking the NGS revolution: managing life science research on shared high-performance computing clusters
por: Dahlö, Martin, et al.
Publicado: (2018)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

Combination of Bortezomib and Mitotic Inhibitors Down-Modulate Bcr-Abl and Efficiently Eliminates Tyrosine-Kinase Inhibitor Sensitive and Resistant Bcr-Abl-Positive Leukemic Cells
por: Bucur, Octavian, et al.
Publicado: (2013)

A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity in vitro: A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like Leukemias
por: Montecchini, Oksana, et al.
Publicado: (2021)

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia
por: El Missiry, Mohamed, et al.
Publicado: (2017)

The benefit of quality control charts (QCC) for routine quantitative BCR-ABL1 monitoring in chronic myeloid leukemia
por: Spiess, Birgit, et al.
Publicado: (2018)

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1(T315I)+ clones in TKI-resistant CML
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2019)

FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-κB signaling activation
por: Yang, Taewoo, et al.
Publicado: (2022)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

Efficient iterative virtual screening with Apache Spark and conformal prediction
por: Ahmed, Laeeq, et al.
Publicado: (2018)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis
por: Baum, Karina J, et al.
Publicado: (2008)

Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus
por: Huang, Zheng-Lan, et al.
Publicado: (2013)

IGF-IR determines the fates of BCR/ABL leukemia
por: Xie, Jingjing, et al.
Publicado: (2015)

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
por: Polillo, Marialuisa, et al.
Publicado: (2015)

Bcr-Abl tyrosine kinase inhibitors- current status
por: Mughal, Anum, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_bp1egvuj7tnur93ca1rp40g712